Intercept Pharma (ICPT): Symphony Health Indicates Above Consensus Ocaliva Sales - Wedbush

October 11, 2016 7:49 AM EDT
Get Alerts ICPT Hot Sheet
Price: $137.41 -0.32%

Rating Summary:
    17 Buy, 3 Hold, 5 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade ICPT Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) and sees growing Ocaliva sales and multiple catalysts in the next 6-18 months.

Symphony Health (SH) estimated just over $5 million for Q3 OCA sales— above consensus of $3.5 million. Based on the monthly estimates for OCA sales for PBC, the analyst estimates Q3 OCA sales of at least $5 million, ahead of the Thomson consensus of ~$3.5 million (range $1.6 million to $7.2 million).

There is no change to estimates at this time since Ocaliva was only launched in June and there is not a consistent capture rate for the Symphony Health monthly estimates compared with reported sales.

No change to the price target of $239.

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $154.00 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Liana Moussatos

Add Your Comment